Trial Profile

Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell Disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Decitabine/tetrahydrouridine (Primary) ; Nicotinamide (Primary)
Indications Sickle cell anaemia
Focus Proof of concept; Therapeutic Use
Sponsors EpiDestiny

Most Recent Events

25 May 2025 Planned End Date changed from 5 Apr 2024 to 30 Apr 2027.
25 May 2025 Planned primary completion date changed from 8 Mar 2024 to 30 Oct 2026.
04 Apr 2023 Planned End Date changed from 3 Mar 2023 to 5 Apr 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com